Q3 2024 Earnings Call Transcript November 18, 2024 Cellectar Biosciences, Inc. misses on earnings expectations. Reported EPS ...

As the Department of Justice slowly turns away from enforcement of pandemic-era fraud, as a round of legal changes are ...

The underwriter has been granted a 30-day option to purchase up to an additional 1,590,000 shares of Ventas's common stock. If such option is exercised, then Ventas plans to enter into an additional ...

A local council has hit back after a pub chain suggested it had "advised" businesses to use "dynamic pricing" after certain ...

The Ventas portfolio also includes outpatient medical buildings ... Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10 ...

Interest and other financing expense in the third quarter of 2024 was approximately $268,000 compared to $302,000 for the third quarter of 2023. Interest and other financing expense will fluctuate as ...

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...

Kennedy Jr. is expected to have significant influence over medical device policies, particularly in areas such as safety, transparency and innovation, according to an Nov. 19 analysis by Medical ...

Supply chain leaders and managers in the medical device industry are often puzzled by the ... my chosen approach aligns with overall business goals and delivers measurable value. A structured approach ...

This investment provides capital for continued growth and expansion, fueling Movemedical’s mission to unite the medical device supply chain and drive ... exceptional value to our growing ...